PBI16 COST ANALYSIS OF TWO TREATMENTS BY INFLIXIMAB (ORIGINATOR AND BIOSIMILAR) FOR PATIENTS WITH RHUMATOÏD ARTHRITIS (RA) OR INFLAMMATORY BOWEL DISEASE (IBD) IN A GROUP OF FRENCH PUBLIC HOSPITALS (UNIHA)
May 1, 2020, 00:00
10.1016/j.jval.2020.04.083
https://www.valueinhealthjournal.com/article/S1098-3015(20)30271-0/fulltext
Title :
PBI16 COST ANALYSIS OF TWO TREATMENTS BY INFLIXIMAB (ORIGINATOR AND BIOSIMILAR) FOR PATIENTS WITH RHUMATOÏD ARTHRITIS (RA) OR INFLAMMATORY BOWEL DISEASE (IBD) IN A GROUP OF FRENCH PUBLIC HOSPITALS (UNIHA)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30271-0&doi=10.1016/j.jval.2020.04.083
First page :
Section Title :
Open access? :
No
Section Order :
10313